clinical trial · NCT05838170
Study of TP-04 in Participants With Papulopustular Rosacea
Papulopustular RosaceaLotilaner Gel, 2.0%Vehicle control gel
brief summary
This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR).
started
Mar 1, 2023
primary completion
Nov 13, 2023
completion
Nov 13, 2023
last updated
Nov 24, 2023
detailed description
This is a Phase 2, multicenter, randomized, double-blind, parallel-group, vehicle-controlled study evaluating the safety, tolerability, and efficacy of Lotilaner Gel, 2.0% (TP-04) applied BID for 12 weeks in participants with moderate to severe PPR.
official title
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of TP-04 in Participants With Papulopustular Rosacea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol